Novo Nordisk to Slash U.S. List Prices for Semaglutide Portfolio from 2027 Amid Rising Competitive Pressure

Novo Nordisk Semaglutide Price Cut 2027: Wegovy & Ozempic List Price Drops to $675 Amid Eli Lilly Zepbound Competition

• Novo Nordisk announced that it will cut the U.S. list price of its leading semaglutide‑based medicines, Wegovy, Ozempic, and Rybelsus, to $675 per month starting January 2027, marking a significant step to improve affordability and access to GLP‑1 therapies for obesity and type 2 diabetes

• The price reduction, representing up to 50% off for Wegovy and 35% for Ozempic, comes as the company faces intensifying competition in the fast‑growing weight‑loss market dominated by Eli Lilly’s Zepbound

• While the move reinforces Novo Nordisk’s commitment to expanding patient access to FDA‑approved semaglutide treatments across multiple indications, analysts suggest the change may be too late to regain leadership as next‑generation GLP‑1 drugs reshape the U.S. obesity and diabetes care landscape

Novo Nordisk has announced a substantial reduction in the U.S. list prices of its semaglutide-based therapies, Wegovy, Ozempic, and Rybelsus, effective January 1, 2027. The new wholesale acquisition cost (WAC) will be set at $675 per month, representing cuts of around 50% for Wegovy and 35% for Ozempic from current levels. The move underscores the company’s ongoing attempt to balance commercial dynamics with affordability challenges in an increasingly competitive market for GLP-1-based weight loss and diabetes treatments.

The announced adjustment aims to ease patient access barriers, particularly for those whose out-of-pocket expenses depend on list prices. Although the decision does not affect existing self-pay or direct-to-patient programs, Novo Nordisk emphasized continued availability through savings initiatives, online pharmacy services, and select telehealth networks.

Beyond its pricing strategy, Novo Nordisk reiterated the clinical strength and versatility of semaglutide, which remains the only GLP-1 molecule with FDA approvals across multiple indications, including obesity, type 2 diabetes, chronic kidney disease, and comorbid cardiovascular conditions. This breadth, the company argues, positions its products uniquely within the class.

However, while the price cut reflects an effort to reinforce access and competitiveness, many analysts view it as a delayed response to mounting market pressure. Eli Lilly’s Zepbound overtook Wegovy in 2025 to become the most prescribed anti-obesity drug, a trend expected to persist through 2026. By the time Novo Nordisk’s lower prices take effect in 2027, market dynamics may have shifted further in favor of newer entrants offering improved access and perceived value.

In essence, this latest move demonstrates Novo Nordisk’s willingness to recalibrate its U.S. pricing strategy, but its impact may be muted by timing and the rapidly intensifying GLP-1 landscape.